| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms.
Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed multiple transactions, raising over $2.5B as a biotech CFO. His equity research experience includes senior roles at Stifel (Head of Healthcare Equity Research), Lazard and Oppenheimer (Head of Healthcare Life Sciences Research). The Wall Street Journal recognized Mr. Sendek as an All-Star Analyst with a #1 ranking in stock picking.
"Joel's financial leadership and expertise in biotech will be extremely valuable as we advance our clinical programs and work to establish the Company as a leader in the targeted alpha radiopharmaceutical field," said Perspective's CEO, Thijs Spoor. "His appointment comes at an exciting time for Perspective, with ongoing progress across all three of our clinical programs. I would like to welcome Joel to our senior team and look forward to his strategic insights and contributions."
Mr. Sendek commented, "Perspective's technology has the potential to significantly expand the breadth of tumors that can be treated with radiopharmaceutical therapy. I'm joining because I view Perspective as the most attractive company within one of the most dynamic subsectors of the biotech industry today. My priority will be to support the advancement of this innovative platform and to help ensure the resources are in place to fully realize its potential."
Mr. Sendek is succeeding Juan Graham, who will be leaving the Company. "I personally would like to thank Juan for his contributions and wish him well in his future endeavors," added Mr. Spoor.
Posted In: CATX
